A 38-year-old male with a history of opioid use disorder on buprenorphine maintenance therapy presents with neuropathic pain and anxiety. A previous provider prescribed gabapentin 800 mg three times daily. He reports that he sometimes takes extra doses because they produce a 'buzz' similar to his prior opioid use, especially when combined with his buprenorphine. The PMHNP reviews his prescription drug monitoring program (PDMP) data, which shows gabapentin prescriptions from three different providers. Which of the following best captures the prescribing concern in this scenario?